Jaypirca is approved for CLL/SLL patients previously treated with covalent BTK inhibitors, offering a new treatment option. The BRUIN-CLL-321 trial showed Jaypirca improved progression-free survival ...

A short film that premiered earlier this month tracks the journeys of three people who discovered a renewed commitment to living their lives to the fullest after being diagnosed with chronic ...

As a diehard enthusiast of video games, Ediz Guner has been attentively following the ebbs and flows of the gaming industry for a long period of time. This, coupled with his hobby of extensively ...

Please provide your email address to receive an email when new articles are posted on . Serious infections in patients with chronic lymphocytic leukemia have doubled despite increased use of ...

Pirtobrutinib was associated with a statistically significant improvement in PFS compared with bendamustine plus rituximab therapy. Topline data were announced from a phase 3 trial evaluating ...

1 Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, United States 2 The University of Texas MD Anderson Cancer Center, UTHealth Houston Graduate School of ...

In patients with chronic lymphocytic leukemia (CLL), regular treatment with immunoglobulin replacement therapy was not associated with a reduced risk of serious infections requiring hospitalization, ...

Jaypirca demonstrated superior overall response rates and progression-free survival trends compared to Imbruvica in the BRUIN CLL-314 trial for CLL/SLL patients. The trial is the first head-to-head ...

Pirtobrutinib shows promising results in treating CLL, outperforming ibrutinib in a pivotal phase 3 trial, paving the way for broader applications. Positive topline results from the phase 3 BRUIN ...

Findings showed pirtobrutinib was noninferior to ibrutinib in both the pre-treated and intent-to-treat populations for the endpoint of ORR. Topline data were announced from a head-to-head phase 3 ...

In the age of targeted therapy, what’s the best long-term strategy to treat chronic lymphocytic leukemia (CLL), the most common leukemia in Western countries? Should treatment be continuous to achieve ...